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Abstract: Mitochondria are organelles with a highly dynamic ultrastructure maintained by a
delicate equilibrium between its fission and fusion rates. Understanding the factors influencing
this balance is important as perturbations to mitochondrial dynamics can result in pathological
states. As a terminal site of nutrient oxidation for the cell, mitochondrial powerhouses harness
energy in the form of ATP in a process driven by the electron transport chain. Contemporaneously,
electrons translocated within the electron transport chain undergo spontaneous side reactions with
oxygen, giving rise to superoxide and a variety of other downstream reactive oxygen species (ROS).
Mitochondrially-derived ROS can mediate redox signaling or, in excess, cause cell injury and even
cell death. Recent evidence suggests that mitochondrial ultrastructure is tightly coupled to ROS
generation depending on the physiological status of the cell. Yet, the mechanism by which changes in
mitochondrial shape modulate mitochondrial function and redox homeostasis is less clear. Aberrant
mitochondrial morphology may lead to enhanced ROS formation, which, in turn, may deteriorate
mitochondrial health and further exacerbate oxidative stress in a self-perpetuating vicious cycle.
Here, we review the latest findings on the intricate relationship between mitochondrial dynamics
and ROS production, focusing mainly on its role in malignant disease.
Keywords: mitochondrial dynamics; mitochondrial ultrastructure; redox signaling; oxidative stress;
reactive oxygen species; superoxide; cancer
1. Introduction
1.1. From Bean to Interconnected Web
In textbooks, mitochondria are classically depicted as round, bean-like organelles [1]. The oval
shape of mitochondria observed by electron microscopy is consistent with the endosymbiotic theory
that mitochondria evolved from a bacterial ancestor [2–4]. However, in living cells, mitochondria
typically display dynamic networks of interconnected tubules with many branching points (Movie S1).
The fluctuating nature of mitochondrial ultrastructure affords these organelles flexibility in regulating
the bioenergetic flux of key molecular elements such as ATP, lipids, proteins, mitochondrial DNA
(mtDNA), metabolites, cofactors, and ions throughout the entire mitochondrial network [5,6].
Small guanosine 5′-triphosphatase (GTPase) proteins like Miro help provide a high degree of
homeostatic heterogeneity within the mitochondrial matrix by trafficking mitochondria along
cytoskeletal filaments within [7,8] or between cells [9], thereby exposing mitochondria to distinct
biochemical milieus [10]. Although mitochondrial motility was predominantly studied in neurons
where mitochondria serve a specialized function [11], recent literature has revealed molecular players
of the neuronal mitochondrial transport machinery that may be deregulated in cancers [12]. In this
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scenario, these molecular motors hijack mitochondria and transfer them into cancer cell peripheries as a
localized energy supply for increased mobility and metastasis of the tumor. Accordingly, mitochondrial
fragmentation is believed to facilitate repositioning of mitochondria in cancer cells [13].
1.2. The Fission/Fusion Machinery
The overall steady-state morphological appearance of the mitochondrial reticulum is governed by
the opposing activities of large GTPases directing either fission or fusion. Fusion of the outer and inner
mitochondrial membrane (OMM and IMM) is mediated by mitofusins Mfn1 [14] or Mfn2 [15] and
optic atrophy 1 (Opa1) [16,17], respectively. Profusion activity has also been reported for mitochondrial
phospholipase D (PLD) [18] and mitofilin [19], which is part of the newly-discovered mitochondrial
contact site and cristae organizing system (MICOS) [20,21]. In response to oxidative stress [22–24]
or during cell division [25], the recruitment and activation of the mitochondrial fission GTPase,
dynamin-related protein 1 (Drp1), shifts the balance toward the fragmented phenotype [26–28].
Oligomerization of Drp1 into a spiral-shaped filament around a mitochondrial tubule precedes the
simultaneous constriction of both OMM and IMM, which occurs in a GTP-dependent manner [29].
Mitochondrial fission factor (Mff), mitochondrial fission 1 (Fis1), or mitochondrial dynamic proteins 49
and 51 (MiD49 and MiD51) are receptor-adapters that actively facilitate Drp1 interaction with the OMM
during mitochondrial division [30–32]. Drp1 is post-translationally regulated via phosphorylation,
ubiquitination, SUMOylation, and S-nitrosylation. For example, phosphorylation at Ser616 by the
protein kinase C isoform δ (PKCδ) is activating, whereas phosphorylation at Ser637 by protein kinase
A (PKA) inhibits Drp1 function [33]. Moreover, activity of the classic GTPase dynamin 2 (Dyn2) is
required for final mitochondrial scission, indicating that this process is complex, requiring multiple
steps and contributing factors [34].
1.3. Linking Mitochondrial Dynamics to Cell Death Pathways
Fragmentation of the mitochondrial network is linked with several physiological indicators of
mitochondrial dysfunction, including loss of mitochondrial membrane potential (∆Ψm), decreased
respiration and oxidative phosphorylation (OXPHOS), metabolic shift towards glycolysis, and
increased mitochondrial ROS formation [33]. Glucose or fatty acid catabolism may also give rise
to fragmented mitochondria, albeit with hyperpolarized ∆Ψm and augmented OXPHOS [35]. Collapse
of the reticular form of mitochondria into fragments represents a key intermediate accompanying the
activation of either salvaging or pro-death pathways depending on the stimulus. Resultant fragments
of dysfunctional mitochondria can be selectively targeted for mitophagy to promote cell survival [36]
or, in severe oxidative stress, trigger the intrinsic pathway of apoptosis (Figure 1) [37]. A common
denominator for apoptotic and mitophagic stress response is the involvement of mitochondrial fission,
perhaps triggered by mitochondrial ROS [38,39].
Intrinsic, or mitochondrial, apoptosis is characterized by increased association of the pro-apoptotic
protein Bcl-2-associated X (Bax) with the OMM [40]. Bax, and its close homolog Bcl-2 homologous
antagonist/killer (Bak), which constitutively resides in OMM, oligomerize to induce mitochondrial
outer membrane permeabilization (MOMP). MOMP is accompanied by the release of pro-apoptotic
factors, including cytochrome C, apoptosis-inducing factor (AIF), second mitochondria-derived
activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO),
Omi/high temperature requirement protein A2 (Omi/HtrA2), and other second-messengers that
initiate either caspase-dependent or caspase-independent cell death [41,42]. Although regulation
of MOMP by mitochondrial dynamics is still elusive, considerable progress has been made
towards visualizing Bax-mediated OMM pore formation in cells by means of super-resolution
microscopy [43–45]. Consistent with a positive role for fission in programmed cell death (PCD),
promoting fusion or inhibiting fragmentation prevents or delays the onset of apoptosis [46] or
mitophagy [47]. Given that evading apoptosis is a hallmark of cancer, correct control of mitochondrial
dynamics is critical for slowing or inhibiting tumor progression [22,36,48–50]. In addition, failure of
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these mitochondrial quality control check-points can contribute to the development of degenerative
pathologies such as type 2 diabetes [51–53], heart and brain ischemia-reperfusion (I/R) injury [54],
cardiovascular disorders [55–59], and neuropathies [59–61] such as Parkinson’s [62] and Alzheimer’s
disease [63]. Mitochondrial dysregulation is also thought to contribute to physiological processes
associated with aging [64,65]. Are fragmented mitochondria a cause or consequence of ROS
overproduction? Is it the severity of mitochondrial dysfunction that discriminates between redox
signaling and oxidative stress? Can oxidative stress be regulated by mitochondrial morphology?
Are there different mitochondrial fission phenotypes? Can we therapeutically treat mitochondrial
dynamics? This review focuses on the interplay between mitochondrial dynamics and ROS
homeostasis relevant to the etiology of malignant neoplastic diseases.Antioxidants 2018, 7, 13 3 of 25 
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2. Modulat on f Mitocho ri l Dynamics by Reactive Oxygen Species
2.1. Mitochondria Are a Prime Source of ROS
A primary function of mitochondria is to ge erate proton-motive force, require for ATP synthesis
during OXPHOS to support cellular processes. As such, mitochondria constitute a major metabolic
hub, or a “molecular furnace”, in which catabolic pathways intersect to oxi ize nutrie ts. Along the
electron transport chain (ETC), up to 2% of electrons leak bef re reaching Complex IV, incompletely
reacting with oxygen in a one-electron reduction to produce su eroxide (anion radical) instead of a
water molecule [66]. Mitochondria are the major producer of superoxide and other downstream ROS
in the cell [67], the main source of mitochondrially-derived superoxide being Complex I and III [68].
Additionally, mitochondrial superoxide is generated by electron-transferring flavoprotein-ubiquinone
oxidoreductase duri g fatty acid oxidation, glycerol-3-phosphate dehydroge ase, and other
IMM-associated oxidoreductases [69]. Superoxide is membrane-impermeant and is readily dismutated
to non-radical, me brane-diffusible, H2O2 by superoxide dis utase (SOD) or non-enzymatic
mechanisms [70,71]. As a membrane- iffusible species, mitochondrially-generated H2O2 has been
implicated in cell-wide redox signal transduction [72–77]. H2O2 can be further reduced by ivalent
metal ions or s peroxide in the Fenton [78] or Haber-Weiss reactions [79], respectively, to produce
the hydroxyl radical ( OH). This highly toxic molecule promiscuously reacts with a broad range of
metabolites, thus inducing oxidative damage [80]. Depending on the physiological context, NADPH
oxidases (NOX) and dual oxidases (DUOX) can further contribute to cellular superoxide formation [81].
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2.2. Mitochondrial ROS and Cancer, a Double-Edged Sword
ROS are well known activators of apoptosis [82,83]. Due to oncogenic mutations, increased
metabolic activity, or decreased mitochondrial function, many cancer types are intrinsically associated
with elevated ROS generation [84–86] and mitochondrial fragmentation [33,87]. In addition to being
a mutagenic motor that can drive a cell out of senescence, conventional anti-cancer strategies utilize
pro-oxidant drugs to push the ROS levels beyond a death-inducing threshold specifically in cancer
but not normal cells [88–91]. A typical example is cisplatin, which stimulates both nuclear DNA
and mtDNA damage with concomitant mitochondrial fission [22] and increased mitochondrial ROS
generation [92]. As proof of concept, antioxidants interfere with the therapeutic mechanism of
cisplatin [93]. In addition to chemical pro-oxidants, singlet oxygen (1O2) itself is a ROS molecule
that has gained particular attention in the treatment of shallow tumors such as skin melanoma
by photodynamic therapy (PDT). In PDT, 1O2 and free radicals are generated by irradiation of a
pre-administered photosensitizing drug to induce apoptotic or necrotic cell death in cancer cells [94,95].
Dwelling in close proximity to the epicenter of oxidative metabolism, mtDNA is considered
particularly vulnerable to free radicals and oxidative damage. The free radical theory of ageing is
defined by the positive correlation between accumulated ROS and mtDNA mutations [96]. Considering
that the mitochondrial genome encodes subunits of four out of five ETC Complexes (Complex I and
III–V), mutations in mtDNA predispose ageing cells to mitochondrial dysfunction in a self-perpetuating
vicious cycle [97]. Intramitochondrial mixing by coordinated mitochondrial fission and fusion cycles
could represent an important complementary mechanism to preserve mtDNA integrity against
oxidative injury [98]. Taken together, observations that ageing is associated with the fragmented
mitochondrial phenotype and mtDNA damage would seem to suggest mitochondrial dynamics and
ROS formation are mutually intertwined physiological processes that contribute to a slow decay of
mitochondrial function during ageing.
2.3. Antioxidant Defense Systems
In order to cope with elevated ROS production, cells utilize a host of intricate antioxidant-defense
mechanisms. The most abundant intracellular antioxidant, glutathione (GSH), participates in H2O2
detoxification through thiol-disulfide interchange catalyzed by glutathione peroxidase (GPX), yielding
oxidized glutathione (GSSG) [99,100]. Glutathione reductase, in turn, plays a key role in maintaining
the reduced form of glutathione [101]. In addition to its direct antioxidant capacity, GSSG contributes
to antioxidant defense by inducing mitochondrial hyper-fusion in an Mfn1- and Mfn2-dependent
manner [102]. Other H2O2 scavengers include catalase, which is mainly located in the peroxisomes
where it converts H2O2 to water and oxygen [103], and the peroxiredoxin (PRX) system [104], relying
upon the thioredoxin (TRX) and thioredoxin reductase catalytic cycle [105,106]. Stable peroxiredoxin 3
depletion in transformed mesothelioma cells leads to a hyper-fused mitochondrial phenotype, which
is rescued by overexpression of mitochondrially-targeted or cytosolic catalase [107]. Additionally,
antioxidant action is inherent in the activity of the uncoupling protein (UCP) family [108,109] and
DJ-1 [110]. Ectopic overexpression of SET, an inhibitor of protein phosphatase 2A, in human embryonic
kidney cancer cells increases UCP2 and UCP3 levels in parallel with Drp1- and Fis1-dependent
mitochondrial fragmentation and diminished autophagic flux [111]. In the mouse model of I/R injury,
DJ-1 elicits cardioprotection by preventing excessive mitochondrial fission [112]. Although antioxidant
systems are recognized therapeutic targets, they are prone to transcriptional activation by oncogenes
and thereby enhance tumorigenesis and chemoresistance [113,114].
3. Signaling Pathways Controlling Mitochondrial Dynamics
ROS-generating stimuli that induce mitochondrial network fragmentation can be divided into
either external insults such as during treatment with pro-oxidants or chemotherapeutic agents, PDT,
ionizing radiation, immune response, or viral infection that incur cell injury, or be part of physiological
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redox signaling, for example during hypoxia. In general, stress response signaling pathways convey
both external and internal cues between a redox-sensitive receptor and the downstream effectors of
the mitochondrial fission machinery (Figure 2). How these signals regulate mitochondrial fission and
converge upon the apoptotic stress response is still rather enigmatic and therefore an area of active
research. This section will review the current trends and paradigms of ROS-mediated signaling that
form a link between redox-sensing elements and mitochondrial dynamics and their role in cancer
invasiveness, tumor progression, and metastasis.
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Figure 2. Simplified relationship between ROS-induced redox signaling and mitochondrial dynamics. 
ROS stimuli are recognized by redox sensors (top), which transduce the signal to their respective 
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fragmented morphology (bottom). As indicated, Ras/ERK MAPK signaling involves multiple kinases. 
Redox sensor for mammalian cyclin C pathway has not yet been determined. 
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ROS stimuli are recognized by redox sensors (top), which transduce the signal to their respective
effector kinases (center). Phosphorylation by these kinases can either inhibit mitochondrial fusion (red)
or stimulate fi sion (gr en) proteins that results in the shift of the overall balance from elongated to
fragmented morphology (bottom). As indicated, Ras/ERK MAPK signaling involves multiple kinases.
Redox sensor for ma malian cyclin C pathway has not yet been determined.
3.1. Nrf2/Keap1 Signaling
The master regulator of cellular stre s response is the transcription factor nuclear factor
(erythroid-derived 2 (Nrf2), which reacts o exogenous stimuli by translocating from the cytosol
to nucleus and initi ting the expression of a broad range of ntioxidant-defense and cytoprotective
genes [115,116]. Since Nrf2 is upregulated in numerous tumors, it has been viewed as a promising
target for cancer chemoprevention and therapy [117]. Kelch-like ECH-associated protein 1 (Keap1)
is an E3 ubiquitin ligase and a redox-sensor for Nrf2 signaling that in the absence of oxidative stress
targets Nrf2 for ubiquitin-mediated destruction [118]. Nrf2 is stabilized in the cytosol upon oxidative
or electrophilic stress. Although Nrf2 was demonstrated to influence mitochondrial bioenergetics [119],
the underlying mechanism is poorly understood. For example, mutant Huntingtin interferes with Nrf2
signaling, which resulted in increased fragmentation of mitochondrial network in response to low-level
H2O2 treatment and increased susceptibility to oxidative stress in striatal cells [120]. Furthermore,
Nrf2 mediates the redox-dependent effect of sulforaphane, an isothiocyanate found in cruciferous
vegetables, on increased mitochondrial fragmentation, Bax induction, and the ensuing apoptosis in
prostate cancer cells [121]. This response was specific to tumor cells as sulforaphane behaved as an
antioxidant and promoted mitochondrial fusion and nephroprotection in parallel experiments using a
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non-transformed kidney cell line. Altogether, these studies imply that activation of the Nrf2 antioxidant
response can be a prospective therapeutic strategy in both neurodegenerative and malignant diseases.
3.2. HIF1α-Mediated Response to Hypoxia
The classic example of redox sensing in cancer is the stabilization of the transcription factor
hypoxia-inducible factor 1α (HIF1α) that allows solid tumors to adapt to low-oxygen stress
by promoting aerobic glycolysis (Warburg’s effect), angiogenesis, and tumor invasion [122,123].
Under normoxia, hydroxylation of HIF1α by the prolyl hydroxylase domain (PHD) family of
dioxygenases results in its binding to the von Hippel-Lindau protein followed by ubiquitin-dependent
destruction [124]. HIF1α is stabilized in the cytosol under hypoxia due to the limited availability of
oxygen for the PHD-mediated hydroxylation step. Stabilized HIF1α binds to the oxygen-insensitive
subunit HIF1β and the heterodimer subsequently translocates to the nucleus to initiate the transcription
of a myriad of hypoxia-response genes to promote metabolic reprogramming stimulating aerobic
glycolysis while suppressing OXPHOS activity [125]. HIF1α induction stimulates expression of
several glycolytic genes including phosphofructokinase, pyruvate kinase, and lactate dehydrogenase.
Paradoxically, hypoxic exposure is accompanied by an initial oxidative burst of superoxide generated
by mitochondria [126,127] or NOX enzymes [128]. The hypoxia-induced superoxide burst can originate
from Complex I [129] or the outer Complex III ubiqinone-binding site [130]. Chandel hypothesized that
the Complex III-derived superoxide signal, which is released into the mitochondrial intermembrane
space, is necessary for PHD inactivation and consequent stabilization of HIF1α at the onset of hypoxia.
This model implicates mitochondria as active oxygen sensors [131].
There is a distinct association between oxygen deprivation and mitochondrial fragmentation in
malignant cells. Hypoxia-induced Drp1 overexpression and mitochondrial fission have been linked to
increased migration and metastatic activity in breast cancer MDA-MB-231 [132] and U251 glioblastoma
cell lines [133]. Importantly, HIF1α stabilization is required for hypoxia-induced mitochondrial
fission [134]. Bioenergetic profiling identified an ovarian cell line (OVCA420) that exhibited fragmented
mitochondria due to increased Drp1 expression [135]. These cells also displayed reduced respiration
and increased glycolysis. In addition, OVCA420 cells failed to stabilize HIF1α in a 1% oxygen
environment reducing cellular fitness to hypoxic conditions. These findings are consistent with the
model that mitochondrial dynamics not only play an important role in cellular energetics, but may
also serve as a sensor for the hypoxic response. Taken together, these studies suggest that HIF1α can
act as a fundamental driver of both mitochondrial fission and cancer progression.
3.3. ASK1/p38 MAPK Pathway
The p38 mitogen-activated protein kinase (MAPK) is stimulated by the apoptosis signal-regulating
kinase 1 (ASK1) protein kinase to transduce redox signals as well as other types of stress, to
stimulate stress response programs, growth or differentiation depending on the signal [136,137].
Cytosolic thioredoxin 1 (Trx1) and mitochondrial thioredoxin 2 (Trx2) act as redox sensors for
ASK1-mediated apoptosis signaling [138]. In their reduced form, TRXs sequester ASK1 from inducing
stress- and cytokine-regulated apoptosis. This inhibition is relieved upon a pro-oxidant stimulus,
which is sensed by intramolecular disulfide bond formation between Cys32 and Cys35 in TRX and
this leads to the dissociation of the free kinase [139]. One role for the p38 MAPK signaling is
in the adaptation of mitochondrial morphology to hypoxia. In response to hypoxia, p38 MAPK
induces mitochondrial fragmentation by upregulating Siah2, which mediates derepression of Drp1
by the mitochondrial scaffolding protein AKAP121 [140]. Siah2 is an E3 ubiquitin ligase that targets
AKAP121 for proteasomal degradation. In addition to p38 MAPK [141], Siah2 is upregulated by
hypoxia-induced Akt signaling most likely through indirect mechanisms [142]. PKCδ-activated p38
MAPK was demonstrated to directly phosphorylate Drp1 to induce its mitochondrial translocation
and subsequent mitochondrial fission in response to succinate challenge [143]. This change in
mitochondrial network ultrastructure was required for promoting human mesenchymal stem cell
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(hMSC) motility via upregulation and redistribution of F-actin. Moreover, pharmacological inhibition
of p38 MAPK prevented mitochondrial fragmentation and the onset of mitophagy in a rat brain I/R
(stroke) model [144]. In addition to p38 MAPK, c-Jun N-terminal kinase (JNK) can also be activated
by ASK1 in response to oxidative stress [145]. JNK has mitochondrial substrates including those
important for apoptosis [146] but a role in stress-induced fission/fusion has yet to be elucidated. These
data indicate that p38-driven mitochondrial fission may represent an important cytological cue to
promote tumorigenesis and metastasis.
3.4. Ras/ERK1/2 MAPK Pathway
The small GTPase Ras, is a well-known effector of the redox-mediated stress response [147] as
well as a potent driver of malignant transformation when constitutively activated by mutation [148].
Collectively with three isoforms (Kras, Nras, and Hras), Ras is one of the most frequently mutated
oncogenes occurring in approximately 25% of human tumors. When tethered to the plasma membrane
through farnesyl and palmitoyl lipid moieties, Ras functions as a molecular switch oscillating
between an active (GTP-bound) and inactive (GDP-bound) state. The GTP and GDP status of Ras
is directed by the activity of guanine nucleotide exchange factors and GTPase-activating proteins,
respectively [149,150]. Normally, Ras transduces external cues such as growth factor and cytokine
stimulation to downstream MAPK cascade effectors composed of rapidly accelerated fibrosarcoma
(Raf) (MAP3K), MAPK/extracellular signal-regulated kinase (MAPK/ERK) kinase 1 and 2 (MEK1/2)
(MAP2K), and ERK1/2 (MAPK), to promote cell proliferation, differentiation, and motility [151].
In addition, Ras directly mediates redox signaling or initiates the oxidative stress response that can
trigger apoptotic cell death [152]. Mechanistically, Ras senses ROS and RNS changes through its
redox-sensitive cysteine found within a conserved consensus signature sequence NKXD, where X
indicates redox-sensitive cysteine (not conserved). The reaction mechanism is thought to involve either
one- or two-electron cysteine oxidation, the former being considered more common and proceeding
through a thiyl radical intermediate RS , where R denotes an alkyl group. RS promotes oxidation of
the bound guanine nucleotide resulting in its release and rapid turnover.
Numerous reports implicate Ras in modulating mitochondrial ultrastructure [153]. For example,
Kashatus and Nascimento et al. reported that ERK2-mediated activating phosphorylation of Drp1 at
Ser616 was required for mitochondrial fragmentation and tumor cell proliferation [154]. Similar effects
of oncogenic Ras activation on the dynamics of mitochondria and tumor progression have been
observed in cells and human melanoma cell lines [155]. In this setting, ERK1/2-dependent Drp1
activation promotes mitochondrial fission, ∆Ψm loss, and mitochondrial ROS generation during
RasG12V-driven tumor transformation. This phosphorylation mark is also used by cyclin B-Cdk1 to
simulate fission at mitosis to allow the efficient partitioning of mitochondria in daughter cells [156].
Overexpression of constitutively-active HrasG12V mutant or MAPK activation was associated with
increased mitochondrial fission and tumor growth in both in vitro human pancreatic cancer and
mouse xenograft models. This fission may be stimulating cell division by generating enough ROS to
serve as both a growth catalysis and mitochondrial segregation. Drp1 depletion by shRNA-mediated
knockdown or expression of phosphorylation-defective mutant prevented mitochondrial fission
and Ras-induced growth. Similarly, pharmacological inhibition of the MAPK pathway led to Drp1
downregulation, increased mitochondrial fusion, and metabolic activity. These findings suggest that
mitochondrial dynamics could be a viable therapeutic strategy for Ras-driven neoplasia.
3.5. The Canonical NF-κB Pathway
The redox-sensitive transcription factor nuclear factor κB (NF-κB) plays a major role in
inflammation but is also commonly overexpressed and aberrantly activated in a variety of cancers.
NF-κB activation is associated with evasion of apoptosis and tumor inflammatory or immune
responses [157,158]. NF-κB is a common name for a dimeric complex formed by the members of
the Rel family including p50, p52, RelA (p65), RelB and c-Rel [159]. NF-κB normally resides in the
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cytosol where it forms inhibitory complexes with members of the IκB protein family (IκBα, IκBβ, IκBγ,
IκBε, IκBζ, p100, p105, and Bcl-3) [160,161]. Upon activation by pro-inflammatory or redox stimuli, the
IκB kinase (IKK) complex composed of IKKα, IKKβ, and NF-κB essential modulator (NEMO) targets
IκB proteins for ubiquitin/proteasome-mediated degradation. This frees NF-κB allowing nuclear
translocation and the execution of inflammatory programs [162,163]. IKKα- and IKKαβ-deficient
mouse embryonic fibroblast (MEF) cells, but not those lacking IKKβ, exhibit a fragmented
mitochondrial network that positively correlate with reduced OPA1 expression [161]. In addition,
both effects could be rescued by ectopic overexpression of IKKα. Curiously, PGC-1α-dependent
mitochondrial biogenesis and ROS production, as well as improved mitochondrial function and
antioxidant capacity, were noted in peripheral blood mononuclear cells obtained from professional
football players who underwent an eight week period of active training, all of which was attributed to
NF-κB activation [164].
Importantly, ROS-dependent NF-κB activation was observed in parallel with increased
mitochondrial Ca2+ levels and mitochondrial fission in immortalized mouse kidney epithelial cells and
mouse splenocytes lacking the mitochondrial tumor suppressor Fus1 [165]. Accordingly, Fus1-deficient
splenocytes exerted increased ∆Ψm and mitochondrial ROS production. Furthermore, NF-κB and
Nrf2 were implicated in cigarette smoke-induced mitochondrial fragmentation, dysfunction, and ROS
generation in human airway smooth muscle (ASM) cells [166]. This was accompanied by increased
Drp1 and decreased Mfn2 expression at both protein and mRNA level. In summary, these results
highlight the central role of NF-κB in regulating mitochondrial structure dynamics.
3.6. AMPK Redox Sensing
As an energy-sensing enzyme, AMP-activated protein kinase (AMPK) is the central gatekeeper
of redox and bioenergetic homeostasis [167–169]. Upon nutrient deprivation, AMPK induces the
activation of catabolic (glycolysis, amino acid and fatty acid oxidation) and inhibition of anabolic
pathways (gluconeogenesis, fatty acid biosynthesis) to restore depleted ATP levels [170]. AMPK can
be allosterically activated by an increased AMP:ATP ratio or directly by low glucose levels [171].
Structurally, AMPK is a heterotrimeric protein composed of catalytic α subunit as well as regulatory β
and γ subunits, each of which has distinct isoforms (two isoforms exist for subunit α and β, three for
γ) [172]. AMPK is frequently downregulated during tumorigenesis, which contributes to the Warburg
phenotype, tumor adaptation, and cancer progression [173]. This is consistent with a tumor suppressor
function for AMPK. However, AMPK activation has been observed in a subset of tumors, which
may represent a survival mechanism for poorly vascularized tumors [174,175]. Apart from being a
core energy-sensor, AMPK is also implicated in redox sensing. Indeed, the presence of H2O2 [176],
superoxide [177], or reactive nitrogen species (RNS), such as NO [178], can stimulate AMPK. AMPK
activity is induced by Trx1-dependent reduction of cysteine residues serving as a redox regulator [179].
An alternative hypothesis claims that oxidative stress stimulates AMPK activity indirectly by elevating
the AMP:ATP ratio [180]. These mechanisms are not mutually exclusive and both may contribute to
AMPK regulation depending on the context.
Mitochondrial ROS levels are kept in check by peroxisome proliferator-activated receptor-gamma
coactivator-1α (PGC-1α)-dependent induction of antioxidant defense mechanisms [181].
AMPK stimulates PGC-1α-dependent mitochondrial biogenesis [182], which may be important as
fusion prevents mitochondrial dysfunction and ROS formation [183]. Conversely, AMPK mediates
energy deprivation-induced mitochondrial fission following Complex I (rotenone) and III (antimycin
A) inhibition by directly phosphorylating Mff [184]. This fragmented mitochondrial phenotype was
observed following mitochondrial stress and is believed to predispose cells to mitophagy [185–187].
A recent study revealed a role for AMPK downstream of Drp1-mediated mitochondrial fission.
Drp1 activity was augmented in brain tumor initiating (BTI) cells due to enhanced activating
phosphorylation status leading to fragmented mitochondrial network morphology and increased cell
survival [188]. Pharmacological inhibition or genetic knockdown of Drp1 was sufficient to induce
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apoptosis, which was reversed in Drp1 and AMPK double-knockdown cells, implying a modulatory
role of Drp1 on AMPK function. In another report, AMPK was stimulated by the concerted activity
of the oncogene Myc and an OMM phospholipase PLD6 resulting in net mitochondrial fusion [189].
The indirect, myc-driven activation of AMPK led to the repression of the transcriptional regulators
Yap and Taz, whose functions are associated with tumor resistance and metastasis, resulting in poor
therapeutic outcome and patient survival [190,191]. Collectively, these investigations identify AMPK
as another key player in integrating oncogenic transformation events to mitochondrial morphology
changes during tumorigenesis. Moreover, manipulating mitochondrial dynamics can influence basic
cancer metabolism, providing a new avenue to attack this disease.
3.7. Cyclin C Connects Oxidative Stress-Induced Fission to Apoptosis
Cyclin C is a highly conserved and ubiquitously expressed transcription factor that serves as
a stress signaling effector that functions in the nucleus and at the mitochondria. Together with
cyclin-dependent kinase 8 (Cdk8), cyclin C normally resides in the nucleus as part of the Mediator
complex to regulate Cdk8 and polymerase II-dependent transcription. In the nucleus, cyclin C-Cdk8
function as co-activators with p53 to induce a subset of stress response genes [192]. Independent
of transcription, cyclin C re-localizes to the mitochondria where it stimulates mitochondrial fission
in response to oxidative stress in both mammalian [22] and yeast [23,24] models. In the cytoplasm,
cyclin C directly activates Drp1 at OMM to facilitate mitochondrial fission. Intriguingly, oxidative
stress-induced mitochondrial fragmentation did not require the Ser616 activating phosphorylation.
This finding indicates that the cell recognizes stress-activated fission differently than that occurring
during mitotic cell division. Furthermore, cyclin C is required for mitochondrial-dependent intrinsic,
but not extrinsic, apoptosis [22]. This role for cyclin C at the mitochondria does not require Cdk8,
suggesting that transcriptional regulation is not involved. In yeast cells, deletion of the mediator
component MED13 released cyclin C into the cytoplasm [193], revealing that cyclin C was necessary
and sufficient to induce complete mitochondrial fragmentation. In stressed yeast cells, cyclin C release
is facilitated by Med13 destruction mediated by the Skp, Cullin, F-box-containing complex (SCF)
ubiquitin ligase and activating phosphorylation by the Slt2/Mpk1 MAPK [194]. Heterozygous deletion
of cyclin C gene (CCNC) has been linked to the progression of acute lymphoblastic leukemia [195],
osteosarcoma [196], and thyroid [197] cancer, suggesting that cyclin C is a bona fide tumor suppressor.
Nevertheless, due to its utility, the cyclin C-mitochondrial axis is emerging as a prospective therapeutic
target for both cancer and neurodegenerative diseases.
3.8. Other Redox Sensing Systems
Other redox signaling proteins including p53 [198], forkhead box O (FOXO) [199,200],
Notch [201], PTEN [202], apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE1/Ref-1) [203],
ataxia-telangiectasia mutated (ATM) [204], activator protein 1 (AP-1), cAMP response element binding
protein (CREB), heat shock factor 1 (HSF1), and specificity protein 1 (SP1) [205,206] have also been
tangentially associated with control of mitochondrial shape and structure. How mitochondrial
dynamics control by these factors is coupled to their redox sensing function remains to be clarified.
4. Modulation of Reactive Oxygen Species by Mitochondrial Dynamics
An increasing body of evidence suggests a reciprocal link between mitochondrial morphology
and ROS formation [207]. According to this hypothesis, mitochondrial shape and structure are
intimately linked to the control of redox homeostasis by modulating ROS as a downstream signal
(Figure 3). We will summarize recent observations of how mitochondrial fission and fusion influence
mitochondrial ROS generation and how mitochondrial dynamics could be exploited as a potential
therapeutic target for medical interventions.
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4.1. Mitochondrial-Derived ROS and Fission, the Vicious Cycle
Increased mitochondrial fragmentation corresponded to an unfavorable prognosis for hepatocellular
carcinoma (HCC) patients presumably due to concurrent Drp1 upregulation and downregulation of
Mfn1 [208]. The fragmented mitochondrial phenotype observed after Drp1 overexpression or Mfn1
knockdown in several HCC cell lines was associated with ROS overproduction, Akt (also known as protein
kinase B) activation, evasion of apoptosis, and induction of general autophagy pathway [208]. Conversely,
Drp1 knockdown or Mfn1 overexpression attenuated ROS generation. Mechanistically, mitochondrial
fission-induced redox activation of Akt promoted Mdm2-dependent ubiquitin-proteasomal degradation
of p53 and IKK-dependent NF-κB activation [208]. Promisingly, mdivi-1, an allosteric and reversible Drp1
inhibitor, induced apoptosis and suppressed the growth of xenograft HCC tumors in immunodeficient
mouse model [208]. Overexpression of Mff in human immortalized fibroblasts was reported to induce
extensive mitochondrial fragmentation and concomitant mitochondrial dysfunction characterized by
∆Ψm loss, inefficient OXPHOS, and subsequent ATP depletion, giving rise to increased oxidative stress
along with concomitant activation of mitophagy and NF-κB-dependent autophagy [209]. Consequently,
Mff-overexpressing fibroblasts exhibited metabolic reprogramming towards aerobic glycolysis and
excessive lactate secretion, which supported the growth of breast cancer cells in a paracrine-like manner
when co-injected into nude mice. Mitochondrial dynamics in cancer-associated stromal cells could
therefore be an important driver of early tumorigenesis in neighboring cancer cells as well as an eventual
therapeutic target. Recent work has shed more light on the role of NF-κB-inducing kinase (NIK), a principal
component of the non-canonical NF-κB pathway, in controlling mitochondrial network dynamics and
subcellular localization of mitochondria in relation to tumor malignancy and invasiveness [210]. Using
loss- and gain-of-function approaches, Jung and Ravi et al. have shown that NIK relies on Drp1 to
mediate mitochondrial fission. This was observed in MEF cells, several cancer cell lines, as well as patient
glioblastoma tissue samples. NIK recruits Drp1 to OMM, facilitates its phosphorylation-dependent
activation, and consequent mitochondrial fragmentation independently of IKKα, IKKβ, and NF-κB.
Consistently, intracellular ROS levels were decreased in both NIK- or Drp1-deficient glioma BT25
cells. Apart from regulating mitochondrial shape, these authors also revealed the ability of NIK to
promote mitochondrial migration and motility towards cell periphery and this coincided with increased
tumor invasiveness.
Dynamic changes in mitochondrial network morphology were recognized to participate in
the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) [211]. Mfn1- or
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Mfn2-deficient MEF cells transduced with the pluripotency factor cocktail containing Oct4, Sox2,
Klf4, and c-Myc (OSKM) displayed fragmented mitochondria and increased ROS formation [212].
Such redox stimulus induced HIF1α stabilization even in the absence of hypoxia. In addition, Mfn1
or Mfn2 depletion in OSKM-treated MEF cells downregulated p53 and p21 and activated Ras and
Raf. Altogether, this contributed to a genetic switch causing metabolic reprogramming from OXPHOS
to glycolysis, which was identified in MEF-derived iPSCs. Analogically, mitochondrial dynamics
has been implicated in the regulation of neural stem cell (NSC) maintenance and self-renewal [213].
Depletion of both Mfn1 and Mfn2 or Opa1 increased mitochondrial fragmentation and superoxide
production without causing oxidative damage, consistent with the signaling role of mitochondrial
fission-induced ROS. When assessed by a neurosphere formation assay, Opa1-deficient NSCs displayed
compromised self-renewal capacity, which was reversed by antioxidant treatments. Conversely,
Drp1-deficient NSCs showed opposite effects. In addition, employing rotenone or genetic deletion of
AIF to specifically induce Complex I-mediated superoxide generation phenocopied the effect of Opa1
loss on neurosphere formation. Further supporting the role of mitochondrial dynamics in determining
the fate of NSCs, mitochondrial morphology-regulated redox signaling was necessary for the execution
of Nrf2-dependent developmental program responsible for the differentiation of NSCs into neurons.
4.2. Metabolic Stimulation
The outcome that metabolic changes have on mitochondrial function and dynamic responses
can be different than those observed following genetic mutation. For example, in a cardiovascular
injury model, hyperglycemic conditions trigger Drp1-mediated mitochondrial fragmentation and
concomitant ROS formation that resulted in mitochondrial permeability transition (MPT)-dependent
apoptosis [214]. This was observed in both rat heart myoblast H9c2 cell line and primary neonatal
cardiomyocytes. In H9c2 cells, mitochondrial fission induced by high glucose levels (20 mM)
stems from elevated mitochondrial metabolism and therefore cannot be associated with defective
mitochondrial function [215]. In analogy, succinate induced Drp1-dependent mitochondrial fission
in hMSC that stimulated ROS generation at high ∆Ψm and OXPHOS activity [143]. These results
indicate that sufficient ROS can be generated by accelerated metabolism to push the cell past the cell
death threshold. An interesting study found that in a model of diabetic nephropathy (DN), exposure
of kidney glomerular mesangial cells to high glucose levels leads to mitochondrial translocation of
Drp1, and subsequent mitochondrial fragmentation, increased ROS production, lipid peroxidation,
p38 MAPK activation, and collagen IV synthesis [216]. Mdivi-1 abolished these effects including the
translocation of Drp1 to mitochondria. Moreover, treatment with the antioxidant N-acetyl-L-cysteine
(NAC) attenuated p38 MAPK phosphorylation, suggesting that Drp1-induced ROS activate p38 MAPK
in a feed-forward regulatory loop. Inquiries into the spatial behavior of mitochondria during metabolic
overload and/or reprogramming deserve further scientific attention not only in cancer but also in
other metabolic disorders such as type 2 diabetes.
4.3. Inflammatory Stimulation
Exposure of mouse embryonic endothelial (MEE) or COS-7 cells to transforming growth factor beta
(TGFβ) led to increased mitochondrial fragmentation, which positively correlated with mitochondrial
superoxide overproduction [217]. Treatment with the TGFβ receptor I (TβRI) kinase inhibitor SB431542
reversed both effects in control MEE cells but not upon knockdown of the TβRI kinase substrate Smad2.
Indeed, the authors went on to show that Smad2 promotes mitochondrial fusion by directly interacting
with Mfn2 and recruiting the Rab and Ras interactor 1 (RIN1) as the guanine nucleotide exchange
factor for Mfn2. Furthermore, an elegant study investigated the molecular underpinnings of osteogenic
dysfunction during TNFα-induced inflammation [218]. TNFα treatment led to increased mitochondrial
ROS formation and Drp1 expression followed by excessive mitochondrial fragmentation. Strikingly,
both symptoms of mitochondrial dysfunction were inhibited by NAC or mdivi-1 treatment, thus further
supporting the notion that superoxide generation and Drp1-mediated fission are intimately interlinked
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phenomena. Furthermore, T cell activation by cluster of differentiation 3 (CD3) antibodies has been
reported to induce mitochondrial fission and ROS production in a Drp1-dependent manner [219].
The activation of Drp1 proceeded through T cell receptor (TCR)-dependent NO signaling and resulted
in production of interleukin 2 (IL-2) and the CD95 via ROS-activated NF-κB. Increased levels of
IL-2 and CD95 led to simultaneously augmented rates of proliferation and extrinsic apoptosis in
CD3-activated T cells.
Lipopolysaccharide (LPS), a surface glycolipid of Gram-negative bacteria and an inflammatory
endotoxin, has been found to stimulate mitochondrial fission, mitochondria- and NOX-derived
superoxide production in immortalized microglial cell line [220]. As a regulated event, the observed
ROS formation occurred downstream of the change in mitochondrial morphology since the effects
were abolished by treatment with the antioxidant oleuropein, a secoiridoid glycoside abundant in
olive leaf, which inhibited Drp1 Ser637 dephosphorylation as well as LPS-induced inflammation.
To summarize, mitochondrial dynamics is an essential component for the inflammatory response that
directs proliferation or cell death depending on the immune signal.
4.4. Anticancer Drugs
In addition to endogenous metabolites and compounds, several chemotherapeutic agents are
proposed to generate ROS through altered mitochondrial morphology. Inhibitor of the hedgehog
signaling pathway, cyclopamine tartrate, elicited antiproliferative and pro-apoptotic behavior in
non-small-cell lung cancer cell lines by inducing mitochondrial fission accompanied by decreased
respiration, increased ∆Ψm, and ROS formation [221]. Cambogin, a naturally-occurring polycyclic
polyprenylated acylphloroglucinol, displayed cytostatic and apoptosis-inducing effects in breast cancer
cell lines. Increased mitochondrial superoxide as well as cytosolic NADPH oxidase 1 (Nox1)-mediated
ROS generation paralleled elevated mitochondrial fission and diminished ∆Ψm following cambogin
treatment [222]. The mechanism of action of cambogin may involve the release of ASK1 from inhibition
by Trx1. Activated ASK1 is then free to stimulate apoptosis via JNK signaling. Nox1 inhibition
or siRNA-mediated knockdown restored normal mitochondrial morphology and ROS production
to basal values. The authors concluded that mitochondrial ROS may converge upon mitochondrial
dynamics downstream of Nox1 activation. This interpretation is again consistent with the feed-forward
regulatory mechanism of mitochondrial ROS-induced ROS generation during structural remodeling of
mitochondria. Moreover, silica nanoparticles were reported to induce mitochondrial fragmentation in
human umbilical vein endothelial cells, which was caused by dysregulation of the fission machinery
proteins, ∆Ψm loss, and accompanied by increased mitochondrial ROS formation and decreased
mtDNA copy number [223]. These studies underscore the fact that mitochondrial ultrastructure
changes can be inherently part of the mechanism of action of ROS-generating chemotherapeutics.
4.5. Ionizing Radiation
Ionizing radiation composed of α particles (
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mitochondrial fission and doxorubicin-induced apoptosis in U-87MG cells. Although the exact
mechanism of VEEV infection is unknown, these data confirm that viruses are capable of impacting on
the fission/fusion machinery to predispose infected cells towards cell death.
4.7. Cigarette Smoke
Cigarette smoke can be regarded as oxidative insult [226]. Cigarette smoke-induced mitochondrial
ROS production that was observed in ASM cells [166] was prevented by Drp1 siRNA-mediated
knockdown. Conversely, Mfn2 knockdown elevated mitochondrial ROS levels in the presence or
absence of cigarette smoke. These results further support the role of mitochondrial dynamics in
modulating mitochondria-generated ROS.
5. Conclusions
Mitochondrial network dynamics has important consequences for physiological homeostasis as
well as in disease states. A vital determinant of mitochondrial structure is the mitochondrial membrane
potential. Within physiological values of ∆Ψm, mitochondria are interconnected and elongated.
However, at both low (mitochondrial dysfunction) and high (metabolic saturation) extremes of ∆Ψm,
mitochondria display a fragmented phenotype accompanied by increased ROS generation. Given that
mitochondrial fission represents an early step in apoptosis, mitochondrial ROS play a fundamental role
at the intersection between these two processes. Although visually similar in appearance, two types
of fragmented state should be distinguished—reversible and irreversible. Whether fragmentation
of mitochondrial network commits cells to cell death is likely to be indicated by the presence of the
latter phenotype. Structurally, this may be the terminal state of ROS-induced ROS vicious cycle that
may involve escalating mitochondrial fission as a core component of this mechanism (Figure 4) [227].
Hence, manipulating mitochondrial morphology towards fission by pro-oxidants or towards fusion by
antioxidants or mdivi-1 seems to be a viable therapeutic strategy in combating cancer and degenerative
diseases, respectively [228].Antioxidants 2018, 7, 13 14 of 25 
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